Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BNZ-1
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Almirall
Deal Size : $62.0 million
Deal Type : Collaboration
Details : The deal would expand Almirall's R&D pipeline with an additional three candidates on top of lead drug BNZ-1.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : $15.0 million
September 01, 2020
Lead Product(s) : BNZ-1
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Almirall
Deal Size : $62.0 million
Deal Type : Collaboration
Lead Product(s) : BNZ-1
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This study followed a phase 1/2, multi-center, open-label, dose-escalation clinical study of BNZ-1 and was designed to assess its safety and activity as a single systemic agent in rCTCL patients that have failed standard of care and other available treat...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 20, 2020
Lead Product(s) : BNZ-1
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNZ-1
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : These data are the first to show therapeutic efficacy of BNZ-1, a multi-cytokine inhibitor selectively targeting three interleukins, IL-2, IL-9, and IL-15. In the study, BNZ-1 treatment was well tolerated with no dose-limiting toxicities or drug-related ...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 11, 2020
Lead Product(s) : BNZ-1
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNZ132-1-40
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 04, 2017
Lead Product(s) : BNZ132-1-40
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNZ132-1-40
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 04, 2017
Lead Product(s) : BNZ132-1-40
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNZ132-1-40
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
A First-in-Human Study of BNZ132-1-40
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 08, 2017
Lead Product(s) : BNZ132-1-40
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
